AIM Therapeutics Inc. Report issue

For profit Phase 2
Founded: Toronto ON Canada (2005)
Status: Defunct (2017)

Organization Overview

First Clinical Trial
2012
NCT01501942
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Alternative names

Ningbo Rongan Biological Pharmaceutical Co. Ltd | Ningbo Rongan Biological Pharmaceutical Co. Ltd.

Active Ingredients

Drugs in Phase 2 Trials (2)

aim-102 (1 trial)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2